Wave Life Sciences, a preclinical biotech developing a nucleic acid therapy platform, filed on Friday with the SEC to raise up to $80 million in an initial public offering.
The Singapore-based company, which was founded in 2012, plans to list on the Nasdaq under the symbol WVE. Jefferies and Leerink Partners are the joint bookrunners on the deal. No pricing terms were disclosed.
